$LPTX
Leap Therapeutics Inc

2023 Q2 Form 10-Q Financial Statement

#000110465923060153 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.560M $3.784M
YoY Change 24.69% 32.87%
% of Gross Profit
Research & Development $11.10M $38.94M
YoY Change -20.94% 400.28%
% of Gross Profit
Depreciation & Amortization $4.000K $4.000K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $14.66M $42.73M
YoY Change -13.24% 301.86%
Operating Profit -$14.66M -$42.73M
YoY Change -13.24% 301.86%
Interest Expense $970.0K $591.0K
YoY Change 5605.88% 2714.29%
% of Operating Profit
Other Income/Expense, Net $300.0K $272.0K
YoY Change -48.89% 635.14%
Pretax Income -$13.39M -$41.86M
YoY Change -21.35% 303.46%
Income Tax
% Of Pretax Income
Net Earnings -$13.39M -$41.86M
YoY Change -21.35% 303.46%
Net Earnings / Revenue
Basic Earnings Per Share -$0.91 -$0.32
Diluted Earnings Per Share -$0.91 -$0.32
COMMON SHARES
Basic Shares Outstanding 119.4M 118.8M
Diluted Shares Outstanding 14.71M 129.3M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.42M $102.0M
YoY Change 0.59% -1.15%
Cash & Equivalents $91.42M $102.0M
Short-Term Investments
Other Short-Term Assets $419.0K $590.0K
YoY Change -2.1% 20.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $93.88M $104.7M
YoY Change 1.56% -0.23%
LONG-TERM ASSETS
Property, Plant & Equipment $13.00K $16.00K
YoY Change -53.57% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $934.0K $15.00K
YoY Change 1456.67% -80.0%
Total Long-Term Assets $1.977M $1.848M
YoY Change 12.2% 93.1%
TOTAL ASSETS
Total Short-Term Assets $93.88M $104.7M
Total Long-Term Assets $1.977M $1.848M
Total Assets $95.86M $106.5M
YoY Change 1.76% 0.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.500M $5.498M
YoY Change -13.94% 28.25%
Accrued Expenses $4.826M $4.388M
YoY Change 95.94% 62.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.76M $10.31M
YoY Change 12.98% 40.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $38.00K $192.0K
YoY Change -91.98%
Total Long-Term Liabilities $38.00K $192.0K
YoY Change -91.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.76M $10.31M
Total Long-Term Liabilities $38.00K $192.0K
Total Liabilities $11.80M $10.50M
YoY Change 8.41% 43.01%
SHAREHOLDERS EQUITY
Retained Earnings -$373.4M -$360.0M
YoY Change 28.34% 31.42%
Common Stock $26.00K $119.0K
YoY Change -70.45% 35.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.06M $28.33M
YoY Change
Total Liabilities & Shareholders Equity $95.86M $106.5M
YoY Change 1.76% 0.61%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$13.39M -$41.86M
YoY Change -21.35% 303.46%
Depreciation, Depletion And Amortization $4.000K $4.000K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$10.19M -$12.70M
YoY Change -16.92% 10.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$348.0K $49.32M
YoY Change
Cash From Investing Activities -$348.0K $49.32M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -29.00K
YoY Change -86.19%
NET CHANGE
Cash From Operating Activities -10.19M -12.70M
Cash From Investing Activities -348.0K 49.32M
Cash From Financing Activities 0.000 -29.00K
Net Change In Cash -10.53M 36.54M
YoY Change -14.08% -412.4%
FREE CASH FLOW
Cash From Operating Activities -$10.19M -$12.70M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129344272
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113248937
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001509745
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129344272
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113248937
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41863000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10376000
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2071000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119410992
CY2022 lptx Operating Lease Additional Liability
OperatingLeaseAdditionalLiability
609000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
99021376
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
136248
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q1 lptx Period To Held Special Meeting
PeriodToHeldSpecialMeeting
P6M
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37990
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
LEAP THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4412575
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
47 Thorndike St, Suite B1-1
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
714-0360
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
LPTX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
119410992
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102038000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65500000
CY2023Q1 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2071000
CY2022Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2099000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
590000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
351000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
104699000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
67950000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
569000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
669000
CY2023Q1 lptx Research And Development Incentive Receivable Noncurrent
ResearchAndDevelopmentIncentiveReceivableNoncurrent
272000
CY2022Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
576000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30000
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
976000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1108000
CY2023Q1 us-gaap Assets
Assets
106547000
CY2022Q4 us-gaap Assets
Assets
70353000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5498000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5657000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4388000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
425000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10311000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11225000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
152000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
262000
CY2023Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
40000
CY2023Q1 us-gaap Liabilities
Liabilities
10503000
CY2022Q4 us-gaap Liabilities
Liabilities
11487000
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
136248
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
67715000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119410992
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99021376
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
119000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
99000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
387886000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
376807000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
355000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
128000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360031000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318168000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
28329000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106547000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70353000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38942000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7784000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3784000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2848000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
42726000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
10632000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-42726000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10632000
CY2023Q1 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
848000
CY2022Q1 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
5000
CY2022Q1 us-gaap Interest Expense
InterestExpense
21000
CY2023Q1 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
272000
CY2022Q1 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
37000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-307000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
235000
CY2023Q1 lptx Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
50000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41863000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10376000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
129344272
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113248937
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41863000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10376000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
227000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-158000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41636000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10534000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-158000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1204000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10376000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
98557000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
9805000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
CY2023Q1 lptx Adjustments To Additional Paid In Capital Redemption Of Warrants
AdjustmentsToAdditionalPaidInCapitalRedemptionOfWarrants
-29000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
227000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1310000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41863000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
28329000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-41863000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-10376000
CY2023Q1 lptx In Process Research And Development Costs Acquired In Connection With Acquistion Of Flame
InProcessResearchAndDevelopmentCostsAcquiredInConnectionWithAcquistionOfFlame
29582000
CY2023Q1 us-gaap Depreciation
Depreciation
4000
CY2022Q1 us-gaap Depreciation
Depreciation
4000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
100000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
104000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1310000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1204000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-307000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
235000
CY2023Q1 lptx Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
50000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
239000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-277000
CY2023Q1 lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
278000
CY2022Q1 lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
38000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2196000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2368000
CY2023Q1 lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-100000
CY2022Q1 lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-106000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-723000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-16000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12700000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11518000
CY2023Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
50362000
CY2023Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1045000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
49317000
CY2023Q1 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
29000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
210000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-29000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-210000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-50000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36538000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11696000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114916000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102038000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103220000
CY2023Q1 lptx Issuance Of Temporary Equity In Connection With Acquisition
IssuanceOfTemporaryEquityInConnectionWithAcquisition
67715000
CY2023Q1 lptx Issuance Of Warrants To Purchase Temporary Equity In Connection With Acquisition
IssuanceOfWarrantsToPurchaseTemporaryEquityInConnectionWithAcquisition
90000
CY2023Q1 lptx Issuance Of Common Stock In Connection With Acquisition
IssuanceOfCommonStockInConnectionWithAcquisition
9805000
CY2023Q1 lptx Issuance Of Warrants For Purchase Of Common Stock In Connection With Acquisition
IssuanceOfWarrantsForPurchaseOfCommonStockInConnectionWithAcquisition
13000
CY2023Q1 lptx Direct And Incremental Costs Of Asset Acquisition Recorded In Accounts Payable
DirectAndIncrementalCostsOfAssetAcquisitionRecordedInAccountsPayable
348000
CY2023Q1 us-gaap Stock Issued1
StockIssued1
1000
CY2023Q1 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
928000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102038000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360031000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41863000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102038000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20088158
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.27
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M29D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8247158
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presentation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q1 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2022 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2022Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2099000
CY2023Q1 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
272000
CY2022Q1 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
37000
CY2021Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1189000
CY2022 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
-2051000
CY2022 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
1064000
CY2022 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-77000
CY2022Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
2099000
CY2023Q1 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
272000
CY2023Q1 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-28000
CY2023Q1 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
2343000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in United States or Australian financial institutions and money market funds. At times, the Company may maintain cash balances in excess of the federally insured amount of $250 per depositor, per insured bank, for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the year ended December 31, 2022 or for the three months ended March 31, 2023.</p>
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.49
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
20088158
CY2023Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
70704000
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
70704000
CY2023Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
40000
CY2023Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
40000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
62074000
CY2023Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
70704000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
50000
CY2023Q1 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2374000
CY2022Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2093000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
398000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
533000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1616000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2526000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4388000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2022 lptx Operating Lease Additional Right Of Use Asset
OperatingLeaseAdditionalRightOfUseAsset
609000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
569000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
577000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
114000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
108000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.27
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M29D
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
339000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
268000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
607000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
30000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
577000
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
49638691
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
50000
CY2023Q1 lptx Number Of Vote On Common Shares
NumberOfVoteOnCommonShares
1
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11917331
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.59
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
8235000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.34
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
64173
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.90
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.25
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.39
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8999
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8270
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0356
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0167
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M1D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5866000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M14D
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41863000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10376000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41863000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10376000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
129344272
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113248937
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q1 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
14217716
CY2022Q1 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
24930483
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58434133
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
48067787
CY2023Q1 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
3469000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001104659-23-060153-index-headers.html Edgar Link pending
0001104659-23-060153-index.html Edgar Link pending
0001104659-23-060153.txt Edgar Link pending
0001104659-23-060153-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lptx-20230331.xsd Edgar Link pending
lptx-20230331x10q.htm Edgar Link pending
lptx-20230331xex10d1.htm Edgar Link pending
lptx-20230331xex10d2.htm Edgar Link pending
lptx-20230331xex10d5.htm Edgar Link pending
lptx-20230331xex10d6.htm Edgar Link pending
lptx-20230331xex10d7.htm Edgar Link pending
lptx-20230331x10q_htm.xml Edgar Link completed
lptx-20230331xex31d1.htm Edgar Link pending
lptx-20230331xex32d1.htm Edgar Link pending
lptx-20230331xex4d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lptx-20230331_cal.xml Edgar Link unprocessable
lptx-20230331_def.xml Edgar Link unprocessable
lptx-20230331_pre.xml Edgar Link unprocessable
lptx-20230331_lab.xml Edgar Link unprocessable